溃疡性结肠炎患者在免疫抑制治疗后发生皮肤淋巴瘤。
Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy.
机构信息
Unit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Ctra de Cadiz s/n, Sevilla 41014, Spain.
出版信息
J Crohns Colitis. 2011 Dec;5(6):608-11. doi: 10.1016/j.crohns.2011.04.015. Epub 2011 May 18.
INTRODUCTION
Biologics are generally safe and well tolerated. However, the risk of haematopoietic cancer in patients with inflammatory bowel disease receiving infliximab has been a growing concern.
CASE PRESENTATION
We report the first case of cutaneous lymphoma after short use of infliximab in 75-year old Caucasian man with a 7-year history of ulcerative colitis.
CONCLUSION
Our current knowledge is not sufficient to rule out an increased risk of lymphoma associated with biologics, or allow definitive conclusions to be drawn about the association of infliximab and lymphoma. However, this case and others direct the attention to that both higher index of suspicion and closer follow up are required if patients are maintained on long-term infliximab together with other immunosuppressive therapy.
简介
生物制剂通常安全且耐受良好。然而，接受英夫利昔单抗治疗的炎症性肠病患者发生血液系统癌症的风险日益令人担忧。
病例介绍
我们报告了首例溃疡性结肠炎 7 年的 75 岁白人男性在使用英夫利昔单抗短时间后发生皮肤淋巴瘤。
结论
我们目前的知识尚不足以排除生物制剂相关淋巴瘤风险增加，也无法对英夫利昔单抗与淋巴瘤的关联做出明确结论。然而，该病例和其他病例都表明，如果患者长期接受英夫利昔单抗联合其他免疫抑制治疗，则需要更高的警惕性和更密切的随访。
Zotero 插件